Answers are grounded in this paper and cite their sources.
Diabetes mellitus is a spectrum of common metabolic disorders arising from various mechanisms all resulting in hyperglycemia. It is a disorder which can lead to coronary artery disease, cerebro- vascular disease, Nephropathy, Diabetic retinopathy, Neuropathy. So, early treatment is necessary to prevent these complications. In this regard, Oral Hypoglycemic drugs are most common type of treatment given for patient. A better cost effective drug can minimize the economic burden on the patients as it is a chronic diseases. The present study was aimed to asses cost effectiveness between glimepride and gliptin that may improve the clinical and economical aspect of patient and increase quality of health in patient. The present study was made to conduct cost effective analysis between glimepride and gliptin. It is a prospective observational study conducted in Basaveshwara Medical College, Hospital and Research Centre and Chitradurga Diabetic Centre for a period of six months. Patients admitted in General medicine above the age of 30 yrs are included. The data was collected from medical records of the patients and documented in suitable designed form.A total of 104 patients were enrolled during the study period, 70 are inpatients and 34 are outpatients. 5 were dropped out from the study. The results reveal that Glimepride has got more efficacy than gliptin. It provided long term Glycemic control than gliptin and also remain less costly compare to gliptin. The one sample student T-test results showed the P value was 0.000*. After follow up glimepride proved to be cost effective drug. Increased health expenditures have led to the need to find out the optimal therapy at the lowest price. This study concluded that Glimepride is more efficacious and cost effective drug than Gliptin. Since diabetes is a chronic disease with long duration, Glimepride might be preferred to Gliptin. It also reveal that glimepride leads to improvements in quality adjusted-life expectancy and is a cost-effective option for the treatment of Type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
DR et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: